Postherpetic neuralgia (PHN) is a common chronic pain disease that persists after the rash (clusters of clear blisters on the surface of the skin) has healed, adversely affecting the quality of life of affected patients. Gabapentin (GPT) and pregabalin (PGB) are two commonly used drugs for the treatment of PHN, but there have been broad concerns regarding their efficacy and safety. Thus, this retrospective cohort study was conducted to investigate the effectiveness and safety of GPT versus PGB in the treatment of PHN. A total of 150 patients with PHN receiving routine antiviral and neurotrophic therapies, admitted between January 2022 and November 2023, were selected. 71 patients who were treated with GPT were included in the control group, while the remaining 79 patients who were given PGB were categorized in the observation group. Information on clinical effectiveness, safety (xerostomia, drowsiness, blurred vision, ataxia, and dizziness), analgesic effect (Visual Analogue Scale [VAS] and time to pain relief), sleep quality (Sleep Quality Scale [SQS] and Pittsburgh Sleep Quality Index [PSQI]), and adverse emotions (Self-rating Anxiety/Depression Scale [SAS/SDS]) was collected for analysis. Compared to the control group, the observation group exhibited significantly higher clinical effectiveness of PGB in the treatment of PHN ( < 0.05). In other aspects, the overall incidence of adverse events such as xerostomia, drowsiness, blurred vision, ataxia, and dizziness ( > 0.05) was equivalent in these two groups. In addition, significantly lower VAS, SQS, PSQI, SAS, and SDS scores were observed in the observation group after treatment, compared with the control group ( < 0.05). The observation group showed evidently shorter time to pain relief than the other group ( < 0.05). PGB is an effective and safe medication for the treatment of PHN, by improving the analgesic effect and sleep quality, and alleviating negative emotions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12968/hmed.2024.0485 | DOI Listing |
Br J Hosp Med (Lond)
December 2024
Department of Neurology, Huai'an Hospital of Huai'an City, Huai'an, Jiangsu, China.
Postherpetic neuralgia (PHN) is a common chronic pain disease that persists after the rash (clusters of clear blisters on the surface of the skin) has healed, adversely affecting the quality of life of affected patients. Gabapentin (GPT) and pregabalin (PGB) are two commonly used drugs for the treatment of PHN, but there have been broad concerns regarding their efficacy and safety. Thus, this retrospective cohort study was conducted to investigate the effectiveness and safety of GPT versus PGB in the treatment of PHN.
View Article and Find Full Text PDFAust J Prim Health
January 2025
School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia; and The George Institute for Global Health, University of New South Wales, Barangaroo, NSW, Australia.
Background The study aimed to understand the acceptability, satisfaction, uptake, utility and feasibility of a quality improvement (QI) intervention to improve care for coronary heart disease (CHD) patients in Australian primary care practices and identify barriers and enablers, including the impact of COVID-19. Methods Within the QUality improvement for Effectiveness of care for people Living with heart disease (QUEL) study, 26 Australian primary care practices, supported by five Primary Health Networks (PHN) participated in a 1-year QI intervention (November 2019 - November 2020). Data were collected from practices and PHNs staff via surveys and semi-structured interviews.
View Article and Find Full Text PDFThe literature in botulinum toxin treatment for painful diabetic neuropathy (PDN), post traumatic neuralgia (PTN), postherpetic neuralgia (PHN) and occipital neuralgia (ON) was reviewed up to Oct 1st, 2024. Using the efficacy criteria set forth by the Assessment and Guideline subcommittee of the American Academy of Neurology, the current levels of efficacy for these conditions could be designated as followings: PDN: B (probably effective, two class II study), PTN: A (effective, two class I studies); PHN: A (effective, two class I studies), ON: (undetermined due to lack of blinded investigations). Due to the small number of patients in these studies, proof of efficacy requires conduction of controlled and blinded studies in large cohorts of patients with longer follow ups.
View Article and Find Full Text PDFChem Sci
November 2024
Molecular Inorganic Chemistry and Catalysis, Inorganic and Structural Chemistry, Center for Molecular Materials, Faculty of Chemistry, Universität Bielefeld Universitätsstrasse 25 D-33615 Bielefeld Germany http://www.ghadwalgroup.de.
The first carbocyclic gallylene [(ADC)Ga(GaI)] and bis-gallylene [(ADC)Ga] (ADC = PhC{N(Dipp)C}; Dipp = 2,6-iPrCH) featuring a central CGa ring annulated between two 1,3-imidazole rings are prepared by KC reductions of [(ADC)GaI]. Treatment of [(ADC)Ga] with Fe(CO) affords complex [(ADC)GaFe(CO)] in which each Ga(i) atom serves as a two-electron donor. [(ADC)Ga] activates white phosphorus (P) and the C -F bond of aryl fluorides (ArF) to yield compounds [(ADC)Ga(P)] and -/-[(ADC)GaF(Ar)], respectively.
View Article and Find Full Text PDFReg Anesth Pain Med
January 2025
Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Introduction: Postherpetic neuralgia (PHN) is a common complication of herpes zoster (HZ). This study aimed to use a large real-world electronic medical records database to determine the optimal machine learning model for predicting the progression to severe PHN and to identify the associated risk factors.
Methods: We analyzed the electronic medical records of 23,326 patients diagnosed with HZ from January 2010 to June 2020.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!